Nexalin Technology, Inc. (NXL) stock
Close on Nov 17, 2026Market cap $33.05MP/E –Yield –
Nexalin Technology, Inc. grew revenue 24.2% to $217.16K over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $33.05M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $33.05M
- P/E ratio
- –
- Price to sales
- 152.22
- Price to book
- 21.75
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $217.16K
- Net income
- -$8.99M
- EPS, diluted
- -$0.48
- Book value per share
- $0.07
- Diluted shares
- 21M
Trading
- Previous close
- $1.56
- Open
- $1.59
- Day's range
- $1.47 – $1.60
- Volume
- 6,966
- Average volume (20 days)
- 28,301
- 52-week range
- $1.31 – $33.60
- RSI (14 days)
- 31.6
- Volatility (1 year)
- 131.5%
- Relative volume
- 0.01×
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | NXL | S&P 500 | Difference | NXL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -36.2% | -4.0% | −32.1 pts | ||
| 3 months | -85.3% | -5.0% | −80.3 pts | ||
| Year to date | -91.0% | +8.2% | −99.3 pts | ||
| 1 year | -95.4% | +11.2% | −106.6 pts | ||
| 3 years | -83.6% | +68.5% | −152.0 pts | -45.2% | +19.0% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases Nexalin Technology filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Update
- Update
- News
About Nexalin Technology
Electromedical & Electrotherapeutic Apparatus
Nexalin designs and creates bioelectronic neurostimulation medical devices designed to address mental health conditions including anxiety, depression, and insomnia without pharmaceutical drugs or psychotherapy. Its core technology utilizes non-invasive electrical waveforms emitted through patient headsets and clinical systems. Offerings include its original Generation 1 cranial electrotherapy stimulation unit, alongside its advanced Generation 2 SYNC clinical console and Generation 3 HALO at-home headset systems. The company also supplies single-use radio-frequency identification electrodes, patient cables, and related licensing services. Customers comprise healthcare providers and licensed medical professionals who administer treatments in clinics or prescribe devices for home use via virtual clinic platforms.
Company profile, executives and historyNexalin Technology stock: common questions
What is Nexalin Technology's stock price?
NXL closed at $1.50 on Nov 17, 2026, down 3.85% on the day. Over the past 52 weeks it traded between $1.31 and $33.60.
What is Nexalin Technology's market cap?
Nexalin Technology was worth $33.05M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is NXL's P/E ratio?
Nexalin Technology lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.48), so it has no meaningful P/E ratio.
How much revenue does Nexalin Technology make?
Nexalin Technology reported revenue of $217.16K for the twelve months to Jun 30, 2026, up 24.2% from a year earlier.
Does Nexalin Technology pay a dividend?
No. Nexalin Technology has not paid a cash dividend over the last twelve months.
How has NXL stock performed over the past year?
Including dividends, NXL returned -95.4% over the past year, against +11.2% for the S&P 500.
How many NXL shares are sold short?
0M shares were sold short at the latest FINRA report, 0.07% of the float, or 1.0 days of average trading volume.
Who are Nexalin Technology's competitors?
Companies most similar to Nexalin Technology by business, industry and size include ITOC, POSC, GTHP, COCH, QTEX.
See a number that looks wrong?